阿片类药物使用障碍治疗 3 年后的护士护理管理:PROUD 群体随机临床试验的二次分析。

IF 10.5 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Gwen T Lapham, Noorie Hyun, Jennifer F Bobb, Paige D Wartko, Abigail G Matthews, Onchee Yu, Jennifer McCormack, Amy K Lee, David S Liu, Jeffrey H Samet, Mohammad Zare-Mehrjerdi, Jordan M Braciszewski, Mark T Murphy, Julia H Arnsten, Viviana Horigian, Ryan M Caldeiro, Megan Addis, Katharine A Bradley
{"title":"阿片类药物使用障碍治疗 3 年后的护士护理管理:PROUD 群体随机临床试验的二次分析。","authors":"Gwen T Lapham, Noorie Hyun, Jennifer F Bobb, Paige D Wartko, Abigail G Matthews, Onchee Yu, Jennifer McCormack, Amy K Lee, David S Liu, Jeffrey H Samet, Mohammad Zare-Mehrjerdi, Jordan M Braciszewski, Mark T Murphy, Julia H Arnsten, Viviana Horigian, Ryan M Caldeiro, Megan Addis, Katharine A Bradley","doi":"10.1001/jamanetworkopen.2024.47447","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>The Primary Care Opioid Use Disorders (PROUD) treatment trial was a 2-year implementation trial that demonstrated the Massachusetts office-based addiction treatment (OBAT) model of nurse care management for opioid use disorder (OUD) increased OUD treatment in the 2 years after implementation began (8.2 more patient-years of OUD treatment per 10 000 primary care patients). The intervention was continued for a third year, permitting evaluation of 3-year outcomes.</p><p><strong>Objective: </strong>To compare OUD medication treatment in intervention and usual care clinics over 3 years of implementation.</p><p><strong>Design, setting, and participants: </strong>This is a preplanned secondary analysis of a cluster randomized implementation trial, conducted in 6 health systems in 5 states (2 primary care clinics per health system) with clinic randomization stratified by system (assignment notification February 28, 2018 [August 31, 2018, in 1 system]). Data were obtained from electronic health records and insurance claims. Eligible patients were those aged 16 to 90 years visiting intervention or usual care clinics from 3 years before to 2 years after randomization. Patients new to clinics during the third year after randomization could not be included because COVID-19-era transitions to virtual care precluded assignment of patients to clinics. Data analysis occurred from November 2023 to September 2024.</p><p><strong>Intervention: </strong>Clinics were randomized to intervention or care as usual. Intervention included 3 implementation components: salary for 1 full-time OBAT nurse per intervention clinic; training and ongoing technical assistance for nurses; and 3 or more primary care buprenorphine prescribers.</p><p><strong>Main outcome and measures: </strong>Patient-years of OUD treatment (buprenorphine or extended-release naltrexone) per 10 000 primary care patients in the 3 years postrandomization. Mixed-effect models adjusted for baseline values of the outcome and included a health system-specific random intercept to account for correlation of clinic pairs within a system.</p><p><strong>Results: </strong>Prerandomization, a total of 290 071 primary care patients were seen, including 130 618 in intervention clinics (mean [SD] age, 48.6 [17.7] years; mean [SD] female, 59.3% [4.0%]) and 159 453 in usual care clinics (mean [SD] age, 47.2 [17.5] years; mean [SD] female, 64.0% [5.3%]). Over 3 years postrandomization, intervention clinics provided 19.7 (95% CI, 11.1-28.4) more patient-years of OUD treatment per 10 000 primary care patients compared with usual care clinics.</p><p><strong>Conclusions: </strong>In this secondary analysis of the PROUD cluster randomized trial, after an added year of the intervention, OUD treatment continued to increase in intervention clinics compared with usual care. The treatment increase over 3 years exceeded that of the first 2 years, suggesting that implementation of the Massachusetts OBAT model leads to ongoing increases in OUD treatment among primary care patients in the third year of implementation.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT03407638.</p>","PeriodicalId":14694,"journal":{"name":"JAMA Network Open","volume":"7 11","pages":"e2447447"},"PeriodicalIF":10.5000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11584924/pdf/","citationCount":"0","resultStr":"{\"title\":\"Nurse Care Management of Opioid Use Disorder Treatment After 3 Years: A Secondary Analysis of the PROUD Cluster Randomized Clinical Trial.\",\"authors\":\"Gwen T Lapham, Noorie Hyun, Jennifer F Bobb, Paige D Wartko, Abigail G Matthews, Onchee Yu, Jennifer McCormack, Amy K Lee, David S Liu, Jeffrey H Samet, Mohammad Zare-Mehrjerdi, Jordan M Braciszewski, Mark T Murphy, Julia H Arnsten, Viviana Horigian, Ryan M Caldeiro, Megan Addis, Katharine A Bradley\",\"doi\":\"10.1001/jamanetworkopen.2024.47447\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Importance: </strong>The Primary Care Opioid Use Disorders (PROUD) treatment trial was a 2-year implementation trial that demonstrated the Massachusetts office-based addiction treatment (OBAT) model of nurse care management for opioid use disorder (OUD) increased OUD treatment in the 2 years after implementation began (8.2 more patient-years of OUD treatment per 10 000 primary care patients). The intervention was continued for a third year, permitting evaluation of 3-year outcomes.</p><p><strong>Objective: </strong>To compare OUD medication treatment in intervention and usual care clinics over 3 years of implementation.</p><p><strong>Design, setting, and participants: </strong>This is a preplanned secondary analysis of a cluster randomized implementation trial, conducted in 6 health systems in 5 states (2 primary care clinics per health system) with clinic randomization stratified by system (assignment notification February 28, 2018 [August 31, 2018, in 1 system]). Data were obtained from electronic health records and insurance claims. Eligible patients were those aged 16 to 90 years visiting intervention or usual care clinics from 3 years before to 2 years after randomization. Patients new to clinics during the third year after randomization could not be included because COVID-19-era transitions to virtual care precluded assignment of patients to clinics. Data analysis occurred from November 2023 to September 2024.</p><p><strong>Intervention: </strong>Clinics were randomized to intervention or care as usual. Intervention included 3 implementation components: salary for 1 full-time OBAT nurse per intervention clinic; training and ongoing technical assistance for nurses; and 3 or more primary care buprenorphine prescribers.</p><p><strong>Main outcome and measures: </strong>Patient-years of OUD treatment (buprenorphine or extended-release naltrexone) per 10 000 primary care patients in the 3 years postrandomization. Mixed-effect models adjusted for baseline values of the outcome and included a health system-specific random intercept to account for correlation of clinic pairs within a system.</p><p><strong>Results: </strong>Prerandomization, a total of 290 071 primary care patients were seen, including 130 618 in intervention clinics (mean [SD] age, 48.6 [17.7] years; mean [SD] female, 59.3% [4.0%]) and 159 453 in usual care clinics (mean [SD] age, 47.2 [17.5] years; mean [SD] female, 64.0% [5.3%]). Over 3 years postrandomization, intervention clinics provided 19.7 (95% CI, 11.1-28.4) more patient-years of OUD treatment per 10 000 primary care patients compared with usual care clinics.</p><p><strong>Conclusions: </strong>In this secondary analysis of the PROUD cluster randomized trial, after an added year of the intervention, OUD treatment continued to increase in intervention clinics compared with usual care. The treatment increase over 3 years exceeded that of the first 2 years, suggesting that implementation of the Massachusetts OBAT model leads to ongoing increases in OUD treatment among primary care patients in the third year of implementation.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT03407638.</p>\",\"PeriodicalId\":14694,\"journal\":{\"name\":\"JAMA Network Open\",\"volume\":\"7 11\",\"pages\":\"e2447447\"},\"PeriodicalIF\":10.5000,\"publicationDate\":\"2024-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11584924/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAMA Network Open\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1001/jamanetworkopen.2024.47447\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA Network Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamanetworkopen.2024.47447","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

重要性:初级保健阿片类药物使用障碍(PROUD)治疗试验是一项为期 2 年的实施试验,该试验表明,马萨诸塞州基于诊室的成瘾治疗(OBAT)护士护理管理阿片类药物使用障碍(OUD)模式在实施 2 年后增加了 OUD 治疗(每 10,000 名初级保健患者增加了 8.2 个 OUD 治疗患者年)。干预措施持续了第三年,因此可以对三年的结果进行评估:比较干预诊所和常规护理诊所在实施干预措施 3 年来的 OUD 药物治疗情况:这是一项预先计划的分组随机实施试验的二次分析,该试验在 5 个州的 6 个卫生系统中进行(每个卫生系统 2 个初级保健诊所),诊所随机化按系统分层(分配通知于 2018 年 2 月 28 日发出[1 个系统于 2018 年 8 月 31 日发出])。数据来自电子健康记录和保险索赔。符合条件的患者是在随机化前 3 年至随机化后 2 年期间前往干预或常规护理诊所就诊的 16 至 90 岁患者。随机化后第三年新到诊所就诊的患者不能纳入其中,因为 COVID-19 时代向虚拟医疗的过渡排除了将患者分配到诊所的可能性。数据分析时间为 2023 年 11 月至 2024 年 9 月:诊所被随机分配到干预或常规护理。干预包括 3 个实施部分:每个干预诊所 1 名全职 OBAT 护士的工资;护士培训和持续的技术援助;3 名或更多的初级保健丁丙诺啡处方者:主要结果:随机化后 3 年内每 10 000 名初级保健患者接受 OUD 治疗(丁丙诺啡或缓释纳曲酮)的患者年数。混合效应模型对结果的基线值进行了调整,并加入了医疗系统特有的随机截距,以考虑系统内诊所对的相关性:随机化前,共有 290 071 名初级保健患者就诊,其中 130 618 人在干预诊所就诊(平均[标码]年龄为 48.6 [17.7]岁;平均[标码]女性为 59.3% [4.0%]),159 453 人在常规保健诊所就诊(平均[标码]年龄为 47.2 [17.5]岁;平均[标码]女性为 64.0% [5.3%])。在随机化后的 3 年中,与常规护理诊所相比,干预诊所为每 10 000 名初级保健患者提供的 OUD 治疗年数增加了 19.7(95% CI,11.1-28.4)年:在 PROUD 分组随机试验的二次分析中,在干预增加一年后,与常规护理相比,干预诊所的 OUD 治疗持续增加。3年的治疗增幅超过了前2年的增幅,这表明马萨诸塞州OBAT模式的实施使初级保健患者的OUD治疗在实施的第三年持续增加:试验注册:ClinicalTrials.gov Identifier:NCT03407638.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Nurse Care Management of Opioid Use Disorder Treatment After 3 Years: A Secondary Analysis of the PROUD Cluster Randomized Clinical Trial.

Importance: The Primary Care Opioid Use Disorders (PROUD) treatment trial was a 2-year implementation trial that demonstrated the Massachusetts office-based addiction treatment (OBAT) model of nurse care management for opioid use disorder (OUD) increased OUD treatment in the 2 years after implementation began (8.2 more patient-years of OUD treatment per 10 000 primary care patients). The intervention was continued for a third year, permitting evaluation of 3-year outcomes.

Objective: To compare OUD medication treatment in intervention and usual care clinics over 3 years of implementation.

Design, setting, and participants: This is a preplanned secondary analysis of a cluster randomized implementation trial, conducted in 6 health systems in 5 states (2 primary care clinics per health system) with clinic randomization stratified by system (assignment notification February 28, 2018 [August 31, 2018, in 1 system]). Data were obtained from electronic health records and insurance claims. Eligible patients were those aged 16 to 90 years visiting intervention or usual care clinics from 3 years before to 2 years after randomization. Patients new to clinics during the third year after randomization could not be included because COVID-19-era transitions to virtual care precluded assignment of patients to clinics. Data analysis occurred from November 2023 to September 2024.

Intervention: Clinics were randomized to intervention or care as usual. Intervention included 3 implementation components: salary for 1 full-time OBAT nurse per intervention clinic; training and ongoing technical assistance for nurses; and 3 or more primary care buprenorphine prescribers.

Main outcome and measures: Patient-years of OUD treatment (buprenorphine or extended-release naltrexone) per 10 000 primary care patients in the 3 years postrandomization. Mixed-effect models adjusted for baseline values of the outcome and included a health system-specific random intercept to account for correlation of clinic pairs within a system.

Results: Prerandomization, a total of 290 071 primary care patients were seen, including 130 618 in intervention clinics (mean [SD] age, 48.6 [17.7] years; mean [SD] female, 59.3% [4.0%]) and 159 453 in usual care clinics (mean [SD] age, 47.2 [17.5] years; mean [SD] female, 64.0% [5.3%]). Over 3 years postrandomization, intervention clinics provided 19.7 (95% CI, 11.1-28.4) more patient-years of OUD treatment per 10 000 primary care patients compared with usual care clinics.

Conclusions: In this secondary analysis of the PROUD cluster randomized trial, after an added year of the intervention, OUD treatment continued to increase in intervention clinics compared with usual care. The treatment increase over 3 years exceeded that of the first 2 years, suggesting that implementation of the Massachusetts OBAT model leads to ongoing increases in OUD treatment among primary care patients in the third year of implementation.

Trial registration: ClinicalTrials.gov Identifier: NCT03407638.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
JAMA Network Open
JAMA Network Open Medicine-General Medicine
CiteScore
16.00
自引率
2.90%
发文量
2126
审稿时长
16 weeks
期刊介绍: JAMA Network Open, a member of the esteemed JAMA Network, stands as an international, peer-reviewed, open-access general medical journal.The publication is dedicated to disseminating research across various health disciplines and countries, encompassing clinical care, innovation in health care, health policy, and global health. JAMA Network Open caters to clinicians, investigators, and policymakers, providing a platform for valuable insights and advancements in the medical field. As part of the JAMA Network, a consortium of peer-reviewed general medical and specialty publications, JAMA Network Open contributes to the collective knowledge and understanding within the medical community.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信